Treatment Outcomes in Patients with Seropositive Versus Seronegative Rheumatoid Arthritis in Phase III Randomised Clinical Trials of Tofacitinib

Overview

Journal RMD Open

Publisher BMJ Publishing Group

Specialty Rheumatology

Date 2019 Mar 20

PMID 30886732

Citations 22

Authors

Paul Bird

Stephen Hall

Peter Nash

Carol A Connell

Kenneth Kwok

David Witcombe

Krishan Thirunavukkarasu

Affiliations

Soon will be listed here.

Abstract

Objectives: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). We examined response to tofacitinib 5 or 10 mg two times a day in patients with seropositive vs seronegative RA.

Methods: Data were pooled from five Phase III studies of conventional synthetic disease-modifying antirheumatic drug (csDMARD)- or biological DMARD-inadequate responders (ORAL Step [NCT00960440]; ORAL Scan [NCT00847613]; ORAL Solo [NCT00814307]; ORAL Sync [NCT00856544]; ORAL Standard [NCT00853385]). 'Serotype' subgroups were: anticyclic citrullinated peptide (CCP) and rheumatoid factor (RF) positive (anti-CCP+/RF+); anti-CCP+/RF negative (-); anti-CCP-/RF+; anti-CCP-/RF-. At month 3, ACR20/50/70 response rates, Disease Activity Score (DAS28-4[ESR])-defined remission (DAS28-4[ESR]<2.6) and low disease activity (LDA; DAS28-4[ESR]≤3.2), changes from baseline (CFB) in Health Assessment Questionnaire-Disability Index (HAQ-DI), Short Form-36 Health Survey (SF-36) physical functioning and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) were evaluated. Safety endpoints were compared.

Results: Baseline demographics/characteristics were similar across subgroups. Tofacitinib significantly improved ACR20/50/70 response rates, DAS28-4(ESR) LDA rates and CFB in HAQ-DI and FACIT-F vs placebo across subgroups. More anti-CCP+/RF+ than anti-CCP-/RF- patients had ACR20/50/70 responses (ACR20/50: both tofacitinib doses; ACR70: 10 mg two times a day). SF-36 physical functioning improved in anti-CCP+/RF+, anti-CCP+/RF- and anti-CCP-/RF+ patients (both tofacitinib doses) and anti-CCP-/RF- patients (10 mg two times a day) vs placebo. More anti-CCP+/RF+ and anti-CCP+/RF- than anti-CCP-/RF- patients achieved DAS28-4(ESR) remission and LDA with tofacitinib 10 mg two times a day. Frequency of adverse events (AEs), serious AEs and discontinuations due to AEs were similar across subgroups.

Conclusion: Generally, tofacitinib efficacy (ACR20/50/70 responses) and safety were similar across subgroups. DAS28-4(ESR) remission rates and SF-36 physical functioning appeared lower in anti-CCP- patients.

Citing Articles

Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients.

Plasencia-Rodriguez C, Martinez-Feito A, Novella-Navarro M, de Diego R, Bonilla G, Gehin J Front Med (Lausanne). 2024; 11:1461396.

PMID: 39296891 PMC: 11410080. DOI: 10.3389/fmed.2024.1461396.

Biomarkers in the diagnosis, prognosis and management of rheumatoid arthritis: A comprehensive review.

Sahin D, Di Matteo A, Emery P Ann Clin Biochem. 2024; 62(1):3-21.

PMID: 39242085 PMC: 11707974. DOI: 10.1177/00045632241285843.

A hierarchical cluster analysis for clinical profiling of tofacitinib treatment response in patients with rheumatoid arthritis.

Janahiraman S, Shahril N, Jayaraj V, Chng S, Eow L, Mageswaren E Clin Rheumatol. 2024; 43(8):2489-2501.

PMID: 38922551 DOI: 10.1007/s10067-024-07035-x.

Towards Personalized Medicine in Rheumatoid Arthritis.

Sharma S, Bluett J Open Access Rheumatol. 2024; 16:89-114.

PMID: 38779469 PMC: 11110814. DOI: 10.2147/OARRR.S372610.

Clinical Phenotypes, Serological Biomarkers, and Synovial Features Defining Seropositive and Seronegative Rheumatoid Arthritis: A Literature Review.

Perera J, Delrosso C, Nerviani A, Pitzalis C Cells. 2024; 13(9.

PMID: 38727279 PMC: 11083059. DOI: 10.3390/cells13090743.

References

Lee E, Fleischmann R, Hall S, Wilkinson B, Bradley J, Gruben D . Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014; 370(25):2377-86. DOI: 10.1056/NEJMoa1310476. View

Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S . Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016; 18:34. PMC: 4730592. DOI: 10.1186/s13075-016-0932-2. View

Szodoray P, Szabo Z, Kapitany A, Gyetvai A, Lakos G, Szanto S . Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun Rev. 2009; 9(3):140-3. DOI: 10.1016/j.autrev.2009.04.006. View

Rantapaa-Dahlqvist S, de Jong B, Berglin E, Hallmans G, Wadell G, Stenlund H . Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003; 48(10):2741-9. DOI: 10.1002/art.11223. View

Goldbach-Mansky R, Lee J, McCoy A, Hoxworth J, Yarboro C, Smolen J . Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2000; 2(3):236-43. PMC: 17811. DOI: 10.1186/ar93. View

Fleischmann R, Cutolo M, Genovese M, Lee E, Kanik K, Sadis S . Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2011; 64(3):617-29. DOI: 10.1002/art.33383. View

Burmester G, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B . Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013; 381(9865):451-60. DOI: 10.1016/S0140-6736(12)61424-X. View

Smolen J, Landewe R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76(6):960-977. DOI: 10.1136/annrheumdis-2016-210715. View

Singh J, Saag K, Bridges Jr S, Akl E, Bannuru R, Sullivan M . 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol. 2015; 68(1):1-26. DOI: 10.1002/art.39480. View

10.

Winthrop K, Yamanaka H, Valdez H, Mortensen E, Chew R, Krishnaswami S . Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014; 66(10):2675-84. PMC: 4285807. DOI: 10.1002/art.38745. View

11.

Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G . Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis. 2005; 65(4):453-8. PMC: 1798112. DOI: 10.1136/ard.2005.041376. View

12.

Lipsky P, van der Heijde D, St Clair E, Furst D, Breedveld F, Kalden J . Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000; 343(22):1594-602. DOI: 10.1056/NEJM200011303432202. View

13.

Sokolove J, Schiff M, Fleischmann R, Weinblatt M, Connolly S, Johnsen A . Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial. Ann Rheum Dis. 2015; 75(4):709-14. PMC: 4819608. DOI: 10.1136/annrheumdis-2015-207942. View

14.

Coombs J, Bloom B, Breedveld F, Fletcher M, Gruben D, Kremer J . Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2009; 69(2):413-6. DOI: 10.1136/ard.2009.108159. View

15.

Steiner G, Smolen J . Autoantibodies in rheumatoid arthritis and their clinical significance. Arthritis Res. 2002; 4 Suppl 2:S1-5. PMC: 3238219. DOI: 10.1186/ar551. View

16.

van Vollenhoven R, Fleischmann R, Cohen S, Lee E, Garcia Meijide J, Wagner S . Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012; 367(6):508-19. DOI: 10.1056/NEJMoa1112072. View

17.

Niewold T, Harrison M, Paget S . Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. QJM. 2007; 100(4):193-201. DOI: 10.1093/qjmed/hcm015. View

18.

Kremer J, Bloom B, Breedveld F, Coombs J, Fletcher M, Gruben D . The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009; 60(7):1895-905. DOI: 10.1002/art.24567. View

19.

Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, Benucci M . Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford). 2009; 48(12):1557-9. DOI: 10.1093/rheumatology/kep314. View

20.

Wallenstein G, Kanik K, Wilkinson B, Cohen S, Cutolo M, Fleischmann R . Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials. Clin Exp Rheumatol. 2016; 34(3):430-42. View